Lamotrigine
( DrugBank: Lamotrigine / KEGG DRUG: Lamotrigine )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 3 |
| 34 | Neurofibromatosis | 5 |
| 38 | Stevens-Johnson syndrome | 1 |
| 113 | Muscular dystrophy | 2 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 114 | Non-dystrophic myotonia syndrome | 5 |
| 115 | Hereditary periodic paralysis | 3 |
| 144 | Lennox-Gastaut syndrome | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
34. Neurofibromatosis
Clinical trials : 179 / Drugs : 259 - (DrugBank : 84) / Drug target genes : 90 - Drug target pathways : 211
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
38. Stevens-Johnson syndrome
Clinical trials : 20 / Drugs : 29 - (DrugBank : 10) / Drug target genes : 15 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
113. Muscular dystrophy
Clinical trials : 826 / Drugs : 680 - (DrugBank : 126) / Drug target genes : 86 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
114. Non-dystrophic myotonia syndrome
Clinical trials : 13 / Drugs : 17 - (DrugBank : 3) / Drug target genes : 6 - Drug target pathways : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
115. Hereditary periodic paralysis
Clinical trials : 11 / Drugs : 20 - (DrugBank : 7) / Drug target genes : 20 - Drug target pathways : 13
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
144. Lennox-Gastaut syndrome
Clinical trials : 130 / Drugs : 79 - (DrugBank : 14) / Drug target genes : 51 - Drug target pathways : 64
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|